Adcendo Closes $135M Series B to Supercharge ADC Development
Adcendo ApS, a biotech company with a sharp focus on developing breakthrough antibody-drug conjugates (ADCs) for treating cancers with dire unmet needs, has just made a bold statement. By closing…
